You are here

  • Home
  • Archive
  • Volume 70, Issue 6
  • MAGE-A family expression is correlated with poor survival of patients with lung adenocarcinoma: a retrospective clinical study based on tissue microarray

Article Text

Article menu
Download PDFPDF
Original article
MAGE-A family expression is correlated with poor survival of patients with lung adenocarcinoma: a retrospective clinical study based on tissue microarray
  1. Meixiang Sang1,2,
  2. Lina Gu1,
  3. Danjing Yin1,
  4. Fei Liu1,
  5. Yishui Lian1,
  6. Xiaochong Zhang1,3,
  7. Shina Liu1,
  8. Weina Huang1,
  9. Yunyan Wu1,
  10. Baoen Shan1,2
  1. 1Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China
  2. 2Tumor Research Institute, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China
  3. 3Clinical Laboratory, Julu County Hospital, Xingtai, Hebei, People's Republic of China
  1. Correspondence to Dr Baoen Shan, Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, People's Republic of China; baoenshan{at}hotmail.com

Abstract

Objectives As the best characterised cancer/testis antigen family members, melanoma-associated antigens (MAGE) have been reported to be expressed in various malignant tumours. However, the expression pattern of MAGE-A family in lung adenocarcinoma (LAC) specimens and their prognostic and therapeutic significance for patients with LAC is still unclear.

Materials and methods Tissue microarray-based immunohistochemistry analysis was used to examine the expression of MAGE-A family members (including MAGE-A1, A2, A3, A4, A6, A10, A11 and A12) in 105 paired LAC specimens and the corresponding pericarcinoma specimens. The association between MAGE-A expression and the clinicopathological parameters, and the 10-year overall survival of patients with LAC were analysed. In addition, the association between MAGE-A expression and the epithelial growth factor receptor (EGFR) amplification and ALK-EML4 rearrangements of patients with LAC were also analysed.

Results The immunohistochemical evaluation revealed that MAGE-A family was expressed in 46.66% of LAC specimens, but not in the corresponding pericarcinoma specimens. MAGE-A expression was not associated with the clinicopathological factors but with worse 10-year survival, and was a poor prognostic marker for patients with LAC. MAGE-A expression was not correlated with EGFR amplification and ALK rearrangements. Interestingly, MAGE-A expression can affect the overall survival of patients with LAC without EGFR amplification or ALK rearrangements, but not affect the overall survival of patients with LAC and EGFR amplification or ALK rearrangements.

Conclusions Molecular assessment of MAGE-A family members could be considered to improve the prognostic evaluation and to provide a new potential therapeutic strategy for patients with LAC.

  • LUNG CANCER
  • TUMOUR MARKERS
  • TUMOUR BIOLOGY

https://doi.org/10.1136/jclinpath-2016-203718

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Handling editor Cheok Soon Lee

    • Contributors BS supplied financial support for the study. MS designed the study and wrote the manuscript. Dr Lina Gu and Dr Danjing Yin performed the TAM analysis and analysed the data. FL and YL performed the FISH. XZ, SL, WH and YW collected the specimens and prepared the TMA blocks.

    • Funding This work was supported by the Natural Science Foundation of Hebei Province, China (No. H2016206410), Financial Supporting Program of Hebei Province (No. (2014) 1257), and Hebei Science and Technology Supporting Program (No. 14277732D). The authors would like to thank Dr Qianglin Duan, a skilled English proofreader from Tongji University, for paper revision.

    • Competing interests None declared.

    • Patient consent Obtained.

    • Ethics approval Medical Ethics Committee of the Fourth Clinical Hospital of Hebei Medical University.

    • Provenance and peer review Not commissioned; externally peer reviewed.